NASDAQ:PALI

Palisade Bio Stock Insider Trading

Healthcare > Biotechnology

Buy PALI

*Your capital is at risk

$1.94

+0.1000 (+5.43%)

At Close: Jun 23, 2026

Palisade Bio Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.69. In total, the insiders bought 47.28M and sold 12.49K PALI shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.69
● Buy	47.28M shares
● Sell	12.49K shares
88% Buy Activity Weak Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 10, 2026 Buy	Common Stock A-Award	Baltera Robert Jr. Director	Director	336 904 Value: $566.0K
Jun 10, 2026 Buy	Common Stock J-Other	Baltera Robert Jr.	Director	0 Value: $0
Jun 10, 2026 Buy	Common Stock J-Other	Zwick Jordan Michael	Director	0 Value: $0
Jun 10, 2026 Buy	Common Stock A-Award	Zwick Jordan Michael Director	Director	336 904 Value: $566.0K
Jun 10, 2026 Buy	Restricted Stock Units M-Exempt	Chuang Emil Director	Director	20 200 Value: $33.9K
Jun 10, 2026 Buy	Common Stock A-Award	Chuang Emil Director	Director	592 300 Value: $995.1K
Jun 10, 2026 Buy	Common Stock M-Exempt	Chuang Emil Director	Director	20 200 Value: $33.9K
Jun 10, 2026 Buy	Restricted Stock Units M-Exempt	Williams Donald Allen Director	Director	60 666 Value: $101.9K
Jun 10, 2026 Buy	Common Stock A-Award	Williams Donald Allen Director	Director	1 498 900 Value: $2.52M
Jun 10, 2026 Buy	Common Stock M-Exempt	Williams Donald Allen Director	Director	60 666 Value: $101.9K
Jun 10, 2026 Buy	Restricted Stock Units M-Exempt	Wei Binxian Director	Director	20 200 Value: $33.9K
Jun 10, 2026 Buy	Common Stock A-Award	Wei Binxian Director	Director	592 300 Value: $995.1K
Jun 10, 2026 Buy	Common Stock M-Exempt	Wei Binxian Director	Director	20 200 Value: $33.9K
Feb 12, 2026 Sell	Common Stock S-Sale	Jones Mitchell Lawrence Chief Medical Officer	Officer	1 989 Value: $3K
Feb 12, 2026 Sell	Common Stock S-Sale	Finley John David CEO, CFO	CEO / President	3 896 Value: $7K
Feb 11, 2026 Buy	Restricted Stock Units M-Exempt	Jones Mitchell Lawrence Chief Medical Officer	Officer	8 000 Value: $13.9K
Feb 11, 2026 Buy	Common Stock M-Exempt	Jones Mitchell Lawrence Chief Medical Officer	Officer	8 000 Value: $13.9K
Feb 11, 2026 Buy	Common Stock M-Exempt	Finley John David CEO, CFO	CEO / President	13 333 Value: $23.2K
Feb 11, 2026 Buy	Restricted Stock Units M-Exempt	Finley John David CEO, CFO	CEO / President	13 333 Value: $23.2K
Feb 09, 2026 Buy	Restricted Stock Units A-Award	Jones Mitchell Lawrence Chief Medical Officer	Officer	787 000 Value: $1.35M
Feb 09, 2026 Buy	Restricted Stock Units A-Award	Finley John David CEO, CFO	CEO / President	2 011 000 Value: $3.46M
Jan 16, 2026 Buy	Common Stock P-Purchase	Williams Donald Allen Director	Director	5 000 Value: $8K
Jan 09, 2026 Buy	Common Stock P-Purchase	Williams Donald Allen Director	Director	5 000 Value: $9K
Oct 06, 2025 Buy	Restricted Stock Units A-Award	Williams Donald Allen Director	Director	182 000 Value: $346.7K
Oct 06, 2025 Buy	Restricted Stock Units A-Award	Wei Binxian Director	Director	60 600 Value: $115.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PALISADE BIO, INC.

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during int...

Read Full Profile Here